Qiagen N.V. (QIA.DE)

QIAGEN N.V. delivers comprehensive "sample to insight" solutions globally, enabling the transformation of biological materials into valuable molecular insights. Their extensive product portfolio addresses various stages of molecular analysis, starting with primary sample technologies. This includes a range of consumables such as kits for nucleic acid stabilization and purification from initial biological samples, as well as manual and automated processing systems for applications like genotyping, gene expression, and viral or bacterial analysis, often utilizing advanced silica membrane and magnetic bead methodologies. They also supply components and kits for purifying nucleic acids from secondary sample types, alongside dedicated instruments and accessories for efficient nucleic acid purification. The company's broad suite of assays covers critical diagnostic and research areas. These include interferon-gamma release tests for tuberculosis, assays for post-transplant monitoring and viral load assessment, and solutions for prenatal testing, detection of sexually transmitted diseases, and human papillomavirus (HPV). Furthermore, QIAGEN provides assays for analyzing complex genomic variants, such as mutations, insertions, deletions, and fusions. For streamlined diagnostics, their "sample to insight" instruments facilitate one-step molecular analysis for challenging syndromes and integrate PCR testing capabilities. QIAGEN also develops and supplies an array of PCR consumables, including quantitative PCR, reverse transcription, and combination kits, essential for gene expression analysis, genotyping, and gene regulation studies. Their offerings extend to human identification and forensics, with STR assays and kits for food contamination detection. The company also features PCR instruments, including cutting-edge digital PCR solutions, and custom-developed OEM consumables. Further bolstering their capabilities, QIAGEN provides predefined and customizable Next-Generation Sequencing (NGS) gene panels, alongside library preparation kits, components, and whole genome amplification solutions. Complementing their vast selection of consumables and instruments, the company offers robust bioinformatics solutions and specialized custom laboratory and genomic services. Serving a diverse customer base, QIAGEN caters to molecular diagnostics laboratories, academic research institutions, pharmaceutical companies, and applied testing sectors. Strategic alliances are maintained with Sysmex Corporation, OncXerna Therapeutics, and Mirati. Founded in 1986, QIAGEN N.V. maintains its corporate headquarters in Venlo, the Netherlands.

No mergers or acquisitions recorded for this company.